// App-Quantinova.ai

9031 : Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.

Researchers

Presenter

  • Nathan A. Pennell

Principal Investigators

  • Alex Mutebi

  • Zheng-Yi Zhou

  • Marie Louise Ricculli

  • Wenxi Tang

  • Helen Wang

  • Annie Guerin

  • Tom Arnhart

  • Kenneth W. Culver

  • Gregory Alan Otterson

Medical Centers

  • Cleveland Clinic, Cleveland, OH

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Analysis Group, Inc., New York, NY

  • Analysis Group, Inc., Montreal, QC, Canada

  • The Ohio State Univerisity, Columbus, OH

Locations

  • United States

  • Canada

Companies

  • Novartis AG

  • Analysis Group, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Anaplastic lymphoma Kinase

  • High affinity nerve growth factor receptor

  • B-Raf proto-oncogene, serine/threonine kinase

  • Programmed death-ligand 1

  • Proto-oncogene tyrosine-protein kinase ROS

  • Ret Proto-Oncogene

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved